News

RapAdmin

HRTBrainImpactBenefits-2
HRTBrainImpactBenefits-22752×1536 506 KB

This study investigates the relationship between lifetime estrogen exposure and late life brain health in a cohort of 352 cognitively normal 70 year old women. Researchers analyzed endogenous estrogen, measured by reproductive lifespan, alongside exogenous estrogen from oral contraceptives and menopausal hormone therapy. Using magnetic resonance imaging, the team evaluated cerebral small vessel disease and Alzheimer disease related cortical thickness. The findings show that a longer reproductive span correlates with reduced small vessel disease burden. Furthermore, the combined use of oral contraceptives and menopausal hormone therapy is associated with significantly greater white matter integrity and a lower risk of severe small vessel disease. Although estrogen exposure did not globally prevent cortical thinning, menopausal hormone therapy preserved cortical thickness specifically in women carrying the APOE epsilon 4 genetic variant.

The trajectory of cognitive aging in women presents a distinct pattern compared to men, driven heavily by the fluctuations of sex hormones over a lifespan. Historically, research into female brain aging has concentrated on Alzheimer disease pathology, specifically the accumulation of amyloid and tau proteins. This paper redirects the focus toward the neurovascular system, proposing that estrogen acts as a primary guardian of cerebral blood vessels. The researchers evaluated a Swedish cohort of women to determine how both natural and synthetic estrogen shape the physical architecture of the aging brain.

The core finding is that cumulative estrogen exposure provides a durable shield against cerebral small vessel disease. Small vessel disease manifests as microscopic bleeds, enlarged perivascular spaces, and degraded white matter, all of which progressively restrict the brain’s metabolic supply and clearance networks. Women who experienced a longer natural reproductive span, defined as the time between first menstruation and menopause, exhibited a significantly lower burden of vascular damage at age 70. The data indicate that endogenous estradiol maintains the elasticity and integrity of the microvasculature, preventing the structural decay that frequently precedes cognitive decline.

Beyond natural estrogen, the study quantified the impact of pharmacological interventions. Oral contraceptives used during early adulthood and menopausal hormone therapy used during the menopausal transition both contributed to enhanced white matter integrity. Notably, women who utilized both oral contraceptives and menopausal hormone therapy throughout their lives demonstrated the highest structural brain health. This points to a cumulative physiological benefit. Exogenous hormones appear to sustain a neurovascular protective window, mitigating the abrupt withdrawal of estrogen that normally accelerates vascular aging during menopause.

The study found no universal protective effect of estrogen against Alzheimer disease cortical atrophy in the general population. The benefits were heavily restricted to the vascular plumbing of the brain. However, a critical exception involved genetic risk. Women carrying the APOE epsilon 4 allele, the strongest genetic risk factor for late onset Alzheimer disease, showed preserved cortical thickness if they had used menopausal hormone therapy. This finding suggests that hormonal interventions might specifically buffer the neurotoxic effects of the APOE epsilon 4 variant.

Ultimately, this research shifts the paradigm of hormonal therapy from a symptom management protocol to a potential strategy for lifelong neurovascular preservation. By maintaining the integrity of the brain’s microscopic blood vessels, continuous estrogen exposure likely supports glymphatic clearance and delays the cascading vascular failures that contribute to dementia. The data make a compelling case for viewing women’s brain health through a lifelong lens, where hormonal events in early adulthood and midlife collectively dictate structural resilience in later decades.

Actionable Insights

For individuals interested in longevity and neuroprotection, this study provides concrete data supporting the vascular benefits of hormone optimization. The primary actionable takeaway is that menopausal hormone therapy is not merely for alleviating vasomotor symptoms; it actively preserves the structural integrity of the brain’s white matter and vascular network. Women who used both oral contraceptives earlier in life and menopausal hormone therapy later in life experienced a 69 percent reduction in the odds of having severe small vessel disease, representing an odds ratio of 0.31. This represents a massive effect size for a pharmacological longevity intervention. Furthermore, combined hormone users exhibited a standardized fractional anisotropy increase of 0.45, indicating significantly superior white matter tract preservation.

For APOE epsilon 4 carriers, the data suggest that menopausal hormone therapy serves as a critical neuroprotective strategy. Hormone therapy users with this genetic variant showed a standardized cortical thickness increase of 0.38 in Alzheimer vulnerable regions compared to non users. Patients and clinicians should collaboratively weigh these substantial structural brain benefits against traditional risks when considering hormone therapy, viewing it as a long term investment in neurovascular span.

Context/Source

RapAdmin

ADHDMortalityRisks-2
ADHDMortalityRisks-22752×1536 509 KB

Attention-deficit hyperactivity disorder is highly correlated with adverse life outcomes and premature mortality. A comprehensive systematic review and meta-analysis of 19 studies encompassing over 15.9 million participants evaluated the association between this disorder and various mortality causes. The data demonstrate that individuals with this condition face a 71% elevated risk of all-cause mortality compared to control populations. This risk increase spans multiple specific causes, including an 89% increase in suicide risk, a 55% increase in fatal injuries, and a 27% increase in natural-cause mortality. Crucially, the meta-analysis reveals that pharmacological treatment for the disorder acts as a powerful protective intervention. Patients utilizing prescribed medication exhibit a 25% reduction in all-cause mortality risk. This underscores the critical importance of accurate diagnosis and sustained medical management for improving long-term health and survival.

Neurodevelopmental conditions are rarely viewed through the lens of classical longevity and lifespan extension. However, population data strongly suggest that psychological and neurobehavioral phenotypes exert a massive influence on mortality. The recent meta-analysis by Corrigan and colleagues aggregates data from nearly 16 million individuals across multiple nations to clarify the true magnitude of mortality risk associated with attention-deficit hyperactivity disorder. The findings reframe the condition from a behavioral or occupational impairment into a systemic risk factor for premature death.

The data reveal a stark reality. Individuals diagnosed with the disorder experience a hazard ratio of 1.71 for all-cause mortality. The elevated mortality is not driven solely by impulsive behaviors leading to accidents, although unintentional and intentional injuries are elevated by 55%. The risk profile is broad. Suicide rates are nearly doubled, reflecting the profound toll of co-occurring conditions like depression, anxiety, and the psychological burden of navigating environments poorly suited to neurodivergent individuals. Furthermore, natural-cause mortality is elevated by 27%, which highlights how the condition indirectly accelerates biological aging and physical decline. Poor impulse control and executive dysfunction frequently translate into adverse health behaviors, including higher rates of substance abuse, poor dietary choices, disrupted sleep architecture, and a failure to adhere to medical protocols for other chronic diseases. Over decades, these friction points compound, degrading metabolic and cardiovascular health.

The most critical finding from a life-extension perspective is the protective effect of pharmacotherapy. The analysis of medication users indicates a hazard ratio of 0.75 for all-cause mortality. This means that medical intervention fundamentally alters the survival trajectory of this population, pulling their mortality risk significantly closer to the baseline of the general public. The exact mechanisms of this mortality reduction likely involve acute improvements in impulse control and emotional regulation, which immediately reduce accident and suicide risks. Long-term benefits likely accrue from improved executive function, allowing individuals to maintain stable employment, cultivate supportive social networks, and reliably engage in positive health behaviors.

The scientific community must acknowledge that effective psychiatric treatment is a primary longevity intervention for affected populations. These findings strongly advocate for public health strategies that remove barriers to diagnosis and ensure continuous access to indicated medications. Addressing the structural determinants of health and reducing the stigma surrounding both the diagnosis and its pharmacological treatments will be necessary to close this substantial mortality gap.

Actionable Insights

For individuals with attention-deficit hyperactivity disorder, securing and adhering to evidence-based pharmacotherapy is one of the most statistically powerful actions available to increase lifespan. The data show a hazard ratio of 0.75 for medication use. In practical terms, this represents a 25% relative risk reduction in all-cause mortality.

The unmedicated condition carries a hazard ratio of 1.71. This means that over a given timeframe, an untreated individual faces a 71% higher chance of death from any cause compared to someone without the condition. Because the disorder increases natural-cause mortality by 27%, affected individuals must proactively optimize routine health behaviors. Executive dysfunction makes adherence to complex health regimens difficult. Therefore, biohackers and patients should prioritize automating their health routines. Strategies include using automated pill dispensers, subscribing to pre-prepared healthy meal deliveries, and utilizing digital scheduling systems to ensure consistent sleep patterns and medical appointments. By treating the underlying neurodevelopmental traits with medication, the cognitive friction associated with maintaining these healthy habits is significantly reduced, directly mitigating both the physiological and behavioral drivers of premature mortality.

Context/Source

RapAdmin

SmartWatchBloodPressure-2
SmartWatchBloodPressure-22752×1536 488 KB

Google researchers trained an AI model on wrist pulse waveforms (photoplethysmography) and motion signals from a Pixel Watch 3 to flag likely hypertension without any cuff calibration. In a prospective five-site US study, 196 adults without heart disease or blood pressure medication wore the watch for about a week and completed 24-hour ambulatory blood pressure monitoring, the clinical gold standard. The watch correctly flagged 66% of people with hypertension and correctly cleared 90% of those without it. A standard office reading caught 55% at the same specificity, but the difference was not statistically significant, and the overall accuracy of the two methods was nearly identical. Performance improved with wear time and leveled off at about an hour of usable data per day over five days. The system is meant as a screening prompt, not a diagnosis, and it was built and tested by the company that plans to sell it.

Roughly half of adults with high blood pressure have no idea they have it. The condition has no symptoms, and the standard way to find it, a cuff reading at a doctor’s office, is both infrequent and surprisingly unreliable. Office readings miss about half of people whose blood pressure is elevated across a full day, partly because some people relax in the clinic and spike everywhere else.

Google’s team took a different approach. Instead of trying to make a watch measure blood pressure directly, which has frustrated engineers for years, they asked a simpler question: does the shape of your pulse, recorded thousands of times over a week, carry a lasting signature of hypertension?

The watch’s green optical sensor records a pulse waveform with every heartbeat. Its accelerometer, during still moments, picks up the faint recoil of the body as the heart ejects blood into the aorta. The researchers first trained a neural network on nearly half a million hours of unlabeled watch data, teaching it to recognize what makes one person’s signals distinctive. They then trained a simple classifier to link those patterns to hypertension in 663 people who had worn a 24-hour blood pressure monitor.

The real test came in 196 new volunteers at five US sites, deliberately diverse in skin tone and age, and enriched for people with borderline readings. Each wore the watch for about a week, wore a 24-hour cuff monitor, took home readings, and had office readings taken. By the 24-hour standard, 39% had hypertension.

The watch caught 66% of them and wrongly flagged 10% of people without it. A single office visit caught 55% with the same false-alarm rate. Overall accuracy was essentially the same for both. The watch did better than a model using only age, sex and body mass index.

What the AI noticed fits known physiology. People it rated as high risk had pulse waves with a slower upstroke and altered reflected-wave timing, which are classic features of stiffer arteries. Their accelerometer traces showed a deeper dip corresponding to blood decelerating in the aorta.

The two methods also missed different people. About half the hypertensives missed in the office were caught by the watch. These are cases of so-called masked hypertension, which are especially easy to overlook.

There are important caveats. The study cohort had far more hypertension than the general population, which makes the device look more precise than it will be in everyday use. Almost all authors work for Google, which has already announced blood pressure features for its newer watches. The model has not been shown to track changes in blood pressure over time, so it cannot tell you whether a new diet or supplement is working. And because a third of the participants had already been flagged once, real-world sensitivity may be closer to the 50% seen during development.

Still, this is the first wrist-based hypertension screen validated against 24-hour monitoring rather than home cuffs. For people who never see a doctor, it could provide a nudge they would otherwise never get.

Actionable insights

The main message is that one normal office reading is weak reassurance. In this study, a single office visit missed 45% of people who were hypertensive over 24 hours. The watch missed 34%.

At matched false-alarm rates (10%), the watch caught about 8 more hypertensives per 76 than the office reading, a 10.5 percentage point gain. That gain was not statistically certain. Overall discrimination was similar: AUROC 0.856 for the watch versus 0.865 for office BP. Both correspond to a standardized separation of about 1.5, which is a large effect.

In a population where 20% have hypertension, a watch alert would raise your probability of having it from 20% to about 62%. No alert would lower it to about 9%. So an alert means “get a cuff,” and no alert does not mean “you’re fine.”

Practical steps:

  • If you are flagged, or if you want to rule out hypertension, do 7 days of home readings (morning and evening, seated, two readings each time) or a 24-hour ambulatory study. Home monitoring over 3 or more days had 89% sensitivity in this study’s subgroup.
  • Wear the watch at least an hour a day with good fit for 5 or more days; accuracy plateaued there.
  • Regarding the use of this feature to judge whether an intervention lowers your blood pressure. That has not been tested.

Context and source

  • Paywalled Paper: Opportunistically Detecting Signs of Hypertension on a Consumer Smartwatch
  • Institutions: Google Research (Cambridge MA, Mountain View CA, Seattle WA); University of Washington; Beth Israel Deaconess Medical Center/Harvard Medical School
  • Country: United States
  • Journal: Nature, published online 5 November 2026
  • Funding: Alphabet Inc.; 14 of 16 authors are Alphabet employees; patent application filed
    Impact evaluation: The impact score of this journal is 56.1 (Clarivate JIF 2025), evaluated against a typical high-end range of 0 to 60+ for top general science journals, therefore this is an Elite impact journal.

RapAdmin

NovosCoreVascularBenefits-2
NovosCoreVascularBenefits-22752×1536 460 KB

A six-month randomized, double-blind trial from the University of Surrey tested NOVOS Core, a daily 15 g powder combining twelve ingredients including glycine, calcium alpha-ketoglutarate, glucosamine, magnesium malate, fisetin, pterostilbene and low-dose lithium, in 61 healthy adults over 40. Among the 43 who finished, the supplement raised brachial flow-mediated dilation, a measure of how well arteries relax, by 2.9 percentage points more than placebo. It also reduced device-estimated pulse wave velocity by 1.18 m/s and lowered systolic blood pressure by 6.1 mmHg. Cholesterol and triglycerides did not change. Modeled 10-year cardiovascular risk fell by 0.45 percentage points, driven almost entirely by blood pressure. Effects appeared within one hour of the first dose. The trial was small, funded by the manufacturer, lost 30% of participants, and cannot say which ingredients matter.

Arteries age before people notice. Long before a heart attack or stroke, the inner lining of blood vessels loses its ability to release nitric oxide and relax, the aorta stiffens, and systolic blood pressure creeps upward. These three changes form the core of what cardiologists call vascular aging, and each predicts future cardiovascular events independently.

A team led by vascular physiologist Christian Heiss at the University of Surrey asked whether a supplement built on geroscience principles could push these markers in the right direction. The product, NOVOS Core, mixes twelve compounds that have each shown some anti-aging promise in worms, flies, mice or small human studies. The list reads like a longevity forum shopping cart: glycine, alpha-ketoglutarate, glucosamine, fisetin, pterostilbene, magnesium, vitamin C, L-theanine, Rhodiola, ginger, hyaluronic acid and a microdose of lithium.

Sixty-one healthy, non-smoking volunteers aged over 40 were randomly assigned to the powder or a taste-matched placebo for six months. The main measure was flow-mediated dilation, an ultrasound test that tracks how much the brachial artery widens after a cuff is released. Heiss’s lab is among the most experienced in the world at this test.

The results were significant. In people taking the supplement, artery dilation rose from about 5.5% to 8.1%, while the placebo group stayed flat. Systolic blood pressure dropped about 6 mmHg more than with placebo, roughly what a standard dose of a single blood pressure drug achieves. A device-based estimate of arterial stiffness also improved. Cholesterol did not budge.

Perhaps the most telling detail is timing. Artery function jumped within an hour of the very first dose, by an amount slightly larger than the six-month effect. That pattern suggests the product works mainly through a fast-acting effect on blood vessel tone that is renewed with each daily dose, rather than by slowly rebuilding aged arteries. The six-month measurements were taken about 24 hours after the last serving, so the study cannot tell lasting repair apart from lingering pharmacology.

There are good reasons for caution. Only 43 people completed the trial. The placebo group started out about five years older. The manufacturer funded the work, and one of its employees is a co-author. The effect on artery dilation is two to three times larger than what is typically seen with well-studied foods like cocoa flavanols or beetroot nitrate, and small trials with surprisingly large effects often shrink when repeated. The stiffness measure came from a cuff device that agrees poorly with the gold-standard method.

Still, the trial was properly randomized and blinded, the primary outcome was declared in advance, and the measurements came from a lab with a strong track record. If the blood pressure effect held up over years, large drug trials suggest it would cut heart attacks and strokes by around a tenth.

The next step is clear: a larger, independent trial with ambulatory blood pressure, gold-standard stiffness measurements and an attempt to identify which of the twelve ingredients is doing the work.

Actionable insights

For adults over 40 with normal to high-normal blood pressure, this trial suggests a specific daily blend may improve how arteries relax and modestly lower systolic pressure. The artery relaxation test improved by 2.9 points from a starting average of 5.5, about a 50% relative gain. In standardized terms that is a Cohen’s d of roughly 1.6, where anything above 0.8 counts as large. Treat that number with suspicion, since effects this big in small trials usually shrink on replication.

Systolic pressure fell about 6 mmHg more than placebo (d about 0.7, medium to large). Large drug-trial meta-analyses link each 5 mmHg drop to about 10% fewer heart attacks and strokes, so if sustained for years this could mean roughly 12% lower relative risk. In absolute terms, for a typical participant with 3% ten-year risk, that is about one event prevented per 220 to 280 people over a decade.

Practical steps: if you try this or any vascular supplement, take home blood pressure readings for two weeks before and after 8 to 12 weeks of use, since your own response is the most useful data you will get. Do not substitute it for prescribed medication. Expect no cholesterol benefit. Single ingredients with independent replication, such as magnesium, dietary nitrate and cocoa flavanols, remain reasonable lower-cost alternatives.

Context and source

  • Open Access Paper: Acute and 6-month vascular effects of a multi-component nutritional supplement: a randomized controlled trial
  • Institution: Faculty of Health and Medical Sciences, University of Surrey, Guildford, with Royal Surrey NHS Foundation Trust and Surrey and Sussex Healthcare NHS Trust; one co-author from NOVOS Labs, New York
  • Country: United Kingdom
  • Journal: European Heart Journal Open (European Society of Cardiology, Oxford University Press)
  • Funding: NOVOS Labs supplied product and placebo and made an unrestricted research contribution
  • Impact evaluation: The impact score of this journal is 4.3 (Clarivate JIF 2025), evaluated against a typical high-end range of 0 to 45+ for top cardiology journals (the flagship European Heart Journal sits near 45), therefore this is a Medium impact journal.

RapAdmin

IGF1DownCogSpeedUp-2
IGF1DownCogSpeedUp-22752×1536 500 KB

Researchers at Loyal Animal Health tested whether lowering insulin-like growth factor 1 (IGF-1) late in life changes how aged dogs think. Twenty-eight laboratory beagles aged 7 to 15, all experienced with cognitive testing, received a single injection of long-acting octreotide, a somatostatin analog that suppresses growth hormone, or saline. Octreotide cut circulating IGF-1 by about 29 percent at its peak, four weeks after dosing. Across three standard tests of attention, cognitive flexibility, and spatial working memory, treated dogs responded faster and were less likely to stall when task rules changed. They were not more accurate: correct answers, error counts, and memory scores were the same in both groups. The authors interpret this as improved processing efficiency and engagement.

Dogs, like people, slow down mentally as they age. Senior dogs take longer to choose, hesitate more when rules change, and are easier to distract. A new study from Loyal, a San Francisco company developing longevity drugs for dogs, asks whether a hormone that drives growth early in life might contribute to that slowdown later on.

The hormone is insulin-like growth factor 1, or IGF-1. Across worms, flies, and mice, animals with weaker growth hormone and IGF-1 signaling tend to live longer, and dwarf mice lacking growth hormone signaling keep their learning and memory skills deeper into old age. In dogs the pattern shows up across breeds: small breeds carry lower IGF-1 and live years longer than giant breeds. People with acromegaly, a condition of excess growth hormone, often have attention and memory problems.

To test the idea directly, the team took 28 laboratory beagles between 7 and 15 years old, all experienced at puzzle-box testing. Half received one intramuscular injection of long-acting octreotide, a drug used in people to treat acromegaly (high growth hormone levels). The other half got saline. Octreotide lowered blood IGF-1 by about 29 percent at its peak, four weeks after the shot, before levels began to rebound.

The dogs then worked through three classic tests. In one, they had to pick a familiar rewarded object while ignoring up to three decoys. In another, the reward rule was flipped so the object they had learned to ignore became the right one. In the third, they had to remember where a block had been after a delay of 20 or 90 seconds.

The treated dogs were quicker. With decoys present, they reached the correct object faster than placebo dogs. When the rules flipped, placebo dogs increasingly froze and made no choice at all, while treated dogs kept responding at their usual rate. In the memory task, treated dogs also responded faster, and the weakest performers appeared to gain the most.

What did not change matters just as much. Treated dogs were no more accurate in any test. They made the same number of errors, chose correctly at the same rate, and remembered locations no better. The authors themselves describe the result as better efficiency and engagement, not better memory.

That distinction leaves room for other explanations. A drug that alters gut hormones and digestion could change how hungry or alert a dog feels when food is the reward. The treated dogs were also already faster on the memory task before they received the drug, which weakens that result. With 14 dogs per group, one dose, and about six weeks of follow-up, the findings are early.

Still, the study offers something the field lacked: a randomized test of lowering IGF-1 in animals that are already old, rather than in mice engineered from birth. It suggests that dialing down this growth signal late in life does not blunt the aging brain in the short term, and may modestly speed it up. For Loyal, which is developing IGF-1-lowering drugs to extend the lives of large dogs, that is a useful early signal. Whether it translates into longer, sharper lives, in dogs or in people, is testing that is in process.

Actionable insights

The dog dose (about 0.9 mg per kg) converts on a body-surface basis to roughly 0.5 mg per kg in humans, around 34 mg for a 70 kg adult, which sits in the upper part of human acromegaly dosing.

How big was the benefit? In the distraction test, treated dogs got about 0.13 seconds faster than placebo dogs, roughly 13 percent of their starting response time. In standard terms that is a large effect (Cohen’s d about 0.9), but with only 14 dogs per group the true effect could plausibly be anywhere from trivial to very large. In the rule-switch test, placebo dogs stalled on about 7 more trials each, out of up to 200. On accuracy, the effect was zero.

The practical take-home is conceptual: modestly lower IGF-1 in late life did not harm cognition over six weeks, and may help. Keep in mind that very low IGF-1 is also linked to higher mortality in older adults, so the target is moderation, not suppression

Context and source

  • Open Access Paper: Octreotide treatment improves multiple domains of cognitive performance in aged beagle dogs
  • Institution: Loyal Animal Health, Inc., San Francisco, California. Animal work was approved by the InterVivo Solutions IACUC and followed Canadian Council on Animal Care guidelines, which indicates testing at a contract research facility in Canada [Confidence: Medium].
  • Country: United States (sponsor), Canada (probable testing site)
  • Journal: Frontiers in Veterinary Science (published 4 November 2026)
  • Impact evaluation: The impact score of this journal is 3.1, evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a Low impact journal.

#### Related Reading:

RapAdmin

FatFreeMassMetobolic-2
FatFreeMassMetobolic-22752×1536 496 KB

Researchers at Pennington Biomedical Research Center analyzed 59,269 UK Biobank participants with both DXA and MRI body composition scans. They asked why higher fat-free mass, usually considered metabolically protective, keeps turning up in large studies as a risk factor for insulin resistance. Absolute fat-free mass and fat-free mass scaled to height were linked to more metabolic syndrome and elevated HbA1c. Fat-free mass as a share of body weight was strongly protective. Interaction models suggested visceral fat had the largest influence on these relationships, while fat infiltrating thigh muscle and sex hormones had smaller, inconsistent effects. The core finding, that the lean-mass paradox mostly reflects overall body size and fat, is plausible.

Ask most fitness coaches and doctors, and they will tell you that more muscle is good for your metabolism. Muscle is the body’s largest consumer of blood sugar, and building it is a standard prescription for preventing diabetes. Yet several large population studies have found the opposite pattern: people with more fat-free mass are more likely to be insulin resistant.

A team led by Candida Rebello at Pennington Biomedical Research Center in Louisiana set out to explain this paradox using one of the richest body composition datasets in the world. They drew on nearly 60,000 UK Biobank volunteers who had both a DXA scan, which estimates lean and fat mass, and an MRI scan, which can measure fat deep in the abdomen and fat marbled through the thigh muscles.

The paradox showed up clearly. People in the top third for total fat-free mass were about twice as likely to have metabolic syndrome as those in the bottom third. But when fat-free mass was expressed as a share of body weight, the picture reversed. Those with the leanest body composition had about one-fifth the rate of metabolic syndrome of those with the least.

The explanation is mostly arithmetic. Larger people carry more of everything: more muscle, more bone, more organ mass and more fat. Fat-free mass is not the same as muscle; only about half of it is skeletal muscle. A high absolute lean mass often simply marks a big body that also carries a lot of fat.

The researchers then tested whether visceral fat, fat infiltrating muscle, or sex hormones changed these relationships. Visceral fat had the clearest influence. Fat infiltrating muscle had effects that were statistically significant but tiny, and sometimes pointed in opposite directions depending on how lean mass was measured. Sex hormones had modest effects that mostly disappeared when men and women were analyzed separately.

The study has notable weaknesses:

  • In UK Biobank, blood tests were taken at enrollment in 2006 to 2010, while body scans began in 2014. The paper does not say which visit its blood data came from. The average age it reports matches the earlier visit, suggesting body composition was measured years after the metabolic outcomes.
  • The authors claim their estimates are precise enough to show real differences across levels of muscle fat. For muscle fat, the confidence intervals overlap.
  • Even MRI-measured thigh muscle volume, the purest muscle measure in the study, showed the same paradoxical pattern. That points to body size rather than poor muscle quality.

For readers, the practical lesson is sound even if the study cannot fully prove it. The absolute amount of lean mass on a body composition scan says little about metabolic health on its own. What matters more is how much fat surrounds it, especially in the abdomen.

Actionable Insights

  • Read your DXA scan for ratios, not totals. In this cohort, people in the top third for lean-mass share of body weight had metabolic syndrome at 7.5 percent, versus 35.9 percent in the bottom third, roughly 79 percent lower. Each 4-percentage-point higher lean share (equivalent to 4 points lower body fat) went with about 55 percent lower odds. [Confidence: Medium, observational]
  • Prioritize visceral fat. Metabolic syndrome rose from 6 percent in the lowest third of visceral fat to 36.6 percent in the highest, about six-fold. Elevated HbA1c rose from 6.6 to 17.2 percent. Many DXA reports estimate visceral fat directly; track it. [Confidence: High for direction]
  • Train for quality, not just quantity:
    • Resistance training builds muscle.
    • Aerobic training and weight loss reduce visceral fat and fat within muscle.
    • The combination addresses both.
  • Do not assume adding lean mass alone protects you. A 3 kg gain in absolute lean mass corresponded to about 45 percent higher odds of metabolic syndrome in this cohort. That almost certainly reflects larger bodies carrying more fat, not harm from muscle, but it means lean mass gained alongside fat gain buys little.

Context and Source

  • Open Acccess Paper: Relationship between fat-free mass and metabolic syndrome is shaped by ectopic fat in a UK Biobank cohort, Published 08 October 2026.
  • Institution: Pennington Biomedical Research Center, Louisiana State University System
  • Country: USA (UK Biobank data)
  • Journal: The Journal of Clinical Endocrinology & Metabolism (Endocrine Society / Oxford University Press).
  • Impact evaluation: The impact score of this journal is 5.1, evaluated against a typical high-end range of 0-45 for endocrinology and metabolism journals (Lancet Diabetes & Endocrinology and Nature Reviews Endocrinology near the top), therefore this is a Medium impact journal. It is the flagship clinical journal of the Endocrine Society.

RapAdmin

vo2maxBiockockrate-2
vo2maxBiockockrate-22752×1536 487 KB

Japanese researchers measured peak oxygen uptake with breath-by-breath gas analysis in 144 men aged 65 to 72 and compared it with DunedinPACE, a blood DNA methylation measure of how fast a person is biologically aging. Men with higher aerobic fitness tended to have a slightly slower pace of aging, and the link held after accounting for age, smoking, and drinking. Using a resampling-based classification analysis, the team proposed 26.2 mL/kg/min as a fitness threshold separating slower from faster agers. Dietary copper and iron intake and HDL cholesterol also tracked with slower aging, while muscle strength did not. The associations were weak, explaining about 3 percent of the variation in aging pace, and the single-timepoint design cannot show that fitness causes slower aging.

Aerobic fitness has one of the strongest track records in longevity research. People who can take up more oxygen during hard exercise live longer and have fewer heart attacks, a pattern that has held across decades of follow-up studies. What has been less clear is whether that fitness shows up in the molecular signals used to track biological aging.

A team led by Takuji Kawamura at Tohoku University and Waseda University tested this in 144 Japanese men aged 65 to 72, all alumni enrolled in a long-running health study. Each man completed a graded cycling test while breathing through a mask that captured every breath, giving a direct measure of peak oxygen uptake, the gold standard for cardiorespiratory fitness. The researchers then analyzed DNA methylation in blood using DunedinPACE, which estimates how many years of biological aging a person accumulates per calendar year. A score of 1.00 means aging at the expected rate; 0.90 would mean about 10 percent slower.

The fitter men did tend to age more slowly by this measure, and the relationship survived adjustment for age, smoking, and drinking. Muscle strength, by contrast, showed no link at all. That points to the heart, lungs, and oxygen-burning capacity of muscle, rather than raw force, as what tracks with the methylation signal.

The team then asked whether a specific fitness level separates slower agers from faster ones. Resampling the data 2,000 times, they settled on 26.2 milliliters of oxygen per kilogram of body weight per minute. That sits above the typical value of about 22.7 for men this age on a cycle test, which the authors read as a sign that above-average fitness is what counts.

Diet appeared in the results too. Men who reported eating more copper and iron per calorie, and men with higher HDL cholesterol, had slower aging scores. Men carrying more visceral belly fat aged slightly faster.

The size of the effect needs to stay in view. Fitness explained roughly 3 percent of the differences in aging pace. In practical terms, a man about one standard step fitter than his peers (4.6 units of oxygen uptake) would be expected to accumulate five or six fewer days of biological aging per year. The cutoff sorted men only modestly better than chance, and the authors concede it has limited value for judging any one person.

There is also a chicken-and-egg problem. Each man was measured once, so the study cannot tell whether fitness slows aging or whether men aging slowly for other reasons find it easier to stay fit. DunedinPACE was also originally built partly from declines in aerobic fitness, so some overlap is baked into the measure.

Still, the work links a trainable trait to a blood-based aging rate in older adults and gives researchers a concrete number to test. The obvious next step is a trial: train older adults past the 26.2 line and see whether their DunedinPACE scores actually fall.

Actionable Insights

  • Get a real measurement. A cardiopulmonary exercise test gives true VO2peak. The study’s 26.2 mL/kg/min line was set on a stationary bike; treadmill tests usually read about 10 to 15 percent higher, so the treadmill equivalent is likely near 29 to 30. [Confidence: Medium]
  • Train the engine. Structured endurance or interval training typically raises VO2peak in older adults by roughly 10 to 20 percent over three to six months, enough to move a man from 23 to the mid 20s.
  • Remember the denominator. The target is per kilogram. An 80 kg man who loses 5 kg of fat while keeping the same absolute oxygen uptake raises his score by about 7 percent.
  • Keep expectations realistic. Each 4.6-unit fitness advantage lined up with about 1.5 percent slower DunedinPACE, or 5 to 6 fewer days of biological aging per year. Being above the cutoff raised the estimated chance of being a slow ager from about 46 percent to about 56 percent. The stronger reason to train comes from outcome studies: each extra 1 MET (3.5 units) of fitness is linked to about 13 percent lower all-cause mortality.
  • If you take metformin, note that one trial in older adults found it blunted mitochondrial and insulin-sensitivity gains from aerobic training. [Confidence: Medium]
  • Copper and iron here were diet estimates, not blood levels. This is not a case for supplements.

Context and Source

  • Open Access Paper: Revisiting the relationship between cardiorespiratory fitness and biological aging: insights from DunedinPACE analysis, published 30 October 2025
  • Institutions: Smart Aging Research Center, Tohoku University (corresponding author); Faculty of Sport Sciences, Waseda University; with co-authors at Juntendo University, Sophia University, Meiji Yasuda Life Foundation, and the Hungarian University of Sports Science
  • Country: Japan (one co-author in Hungary)
  • Journal: GeroScience (2026)
  • Impact evaluation: The impact score of this journal is 4.9, evaluated against a typical high-end range of 0-20 for aging and geroscience journals (Nature Aging sits near the top of that range), therefore this is a Medium impact journal.

RapAdmin

VibrationsAndNitricOxide-2
VibrationsAndNitricOxide-22752×1536 488 KB

Finnish researchers tested whether manipulating blood vessels could push proteins out of the human brain and into the bloodstream. Twenty-nine healthy adults aged 27 to 61 received sublingual nitroglycerin, a nitric oxide donor that relaxes arteries and lowers blood pressure, combined with 37 minutes of patterned whole-body vibration designed to stimulate the mechanosensitive Piezo1 channel. After the combined session, blood levels of amyloid-beta 40, amyloid-beta 42 and the astrocyte protein GFAP rose by roughly 30 to 35 percent, and the size of the rise tracked how far blood pressure fell. MRI showed brain tissue signal darkening, more fluid around the brain and brighter signal in posterior venous sinuses. Larger proteins, neurofilament light and phosphorylated tau, did not change. The findings hint at a non-invasive way to boost brain clearance, but the study was small and short, and its key blood measurements had no control arm.

Every night while you sleep, your brain rinses itself. Cerebrospinal fluid washes through brain tissue and carries away waste proteins, including the amyloid-beta that clumps into plaques in Alzheimer’s disease. This plumbing, often called the glymphatic system, appears to falter with age, and many researchers suspect the failure begins years before memory does. A team led by Vesa Kiviniemi at the University of Oulu in Finland asked a direct question: can we turn that drainage up in awake humans?

Their approach targeted the blood vessels that drive brain fluid flow. Nitric oxide relaxes arteries, and in mice, lowering blood pressure with nitric oxide donors pushes cerebrospinal fluid tracers out of the skull and into the blood. A second lever is Piezo1, a channel in vessel walls that responds to mechanical force. Gentle mechanical stimulation of Piezo1 in mice restores sluggish lymphatic drainage in the neck. The Finnish group combined both. Volunteers placed a nitroglycerin tablet under the tongue, the same drug used for angina, then lay on a vibrating mattress that cycled between 22 and 50 hertz in a pattern meant to keep Piezo1 responsive rather than numb.

The results were clear in direction, if modest in scale. Blood pressure fell by about 15 percent at its lowest point. Blood levels of two forms of amyloid-beta and of GFAP, a protein made by the brain’s astrocyte support cells, rose by roughly a third after correcting for the blood thinning that nitroglycerin causes. People whose blood pressure dropped the most showed the biggest protein rises. Two larger brain proteins, neurofilament light and phosphorylated tau, did not budge, which the authors read as a size filter on the exit route.

Brain scans told a parallel story. A clinical MRI sequence sensitive to the protein content of water showed the whole brain darkening slightly, the fluid space around the brain expanding by about 6.5 milliliters, and signal brightening in two large veins at the back of the head. Blood amyloid levels correlated, weakly, with that venous signal. Changes were larger in older participants. Nitroglycerin alone reproduced much of the brain darkening, vibration alone did little the scanner could detect, and the combination affected a wider area of brain than either alone.

The authors draw a parallel to sleep. Nitroglycerin amplified slow oscillations in blood vessel diameter near 0.1 hertz and breathing-linked pulsations, rhythms that intensify in deep sleep and are thought to pump fluid through the brain.

The study has important gaps. It enrolled 29 healthy adults and measured blood proteins once, about 90 minutes after treatment. It did not measure blood proteins at all after vibration alone, nitroglycerin alone or a sham session. A rise in blood amyloid could mean more protein leaving the brain, but it could also mean slower removal of amyloid by the liver and kidneys while blood pressure is low, or a temporary loosening of the blood-brain barrier. Nobody yet knows whether repeated treatment would lower brain amyloid or protect memory.

What the paper does establish is that human brain fluid dynamics respond measurably, within a couple of hours, to deliberate vascular manipulation. That moves the brain’s drainage system closer to being a practical therapeutic target rather than a purely theoretical one.

Insights

  1. In this trial, one volunteer taking nitroglycerin vomited and withdrew, and others had headaches or nausea. Combining nitrates with PDE5 inhibitors such as tadalafil or sildenafil can cause dangerous, potentially fatal drops in blood pressure. For repeated or long-term use for this purpose: Safety Data Absent.
  2. The benefit measured is a short-term biomarker shift, not a health outcome. Blood amyloid rose about a third, a moderate effect (Cohen’s d about 0.5, meaning the average person moved about half of the normal person-to-person spread). The size of the blood pressure drop explained roughly 25 to 40 percent of the variation in that rise. Memory, plaque load and dementia risk were not measured.
  3. Deep sleep naturally produces similar vascular pulsations. Long-term blood pressure control has real outcome data: in the SPRINT MIND trial, intensive control lowered the risk of mild cognitive impairment by about 19 percent (hazard ratio 0.81).
  4. Vibration platforms are low risk, but here vibration alone produced only small imaging changes and was never tested on blood biomarkers.
  5. Endothelial nitric oxide production declines with age. Regular aerobic exercise is the best-documented way to maintain it.

Context and Source

  • Open access Paper: Vasomechanic treatment is associated with increased efflux of human brain proteins
  • Institution: Oulu Functional Neuroimaging, University of Oulu and Oulu University Hospital, with collaborators at Lund University, University of Eastern Finland and Kuopio University Hospital, University of Rochester, and University of Copenhagen (Maiken Nedergaard’s group)
  • Country: Finland (lead), with Sweden, USA and Denmark
  • Journal: Nature Communications
  • Impact evaluation: The impact score of this journal is 18.1, evaluated against a typical high-end range of 0-60+ for top general science, therefore this is a High impact journal.

Related Reading:

RapAdmin

RecoveryAsAgingMeasure-2
RecoveryAsAgingMeasure-22752×1536 426 KB

Researchers from Swedish Medical Center and the University of Denver argue that aging is best understood as a progressive loss of “biological self-correction”: the body’s ability to sense a disturbance, mount a proportionate response, repair damage, switch the response off and recover while keeping reserve for the next challenge. Rather than replacing the hallmarks of aging, the framework treats them as candidate mechanisms behind impaired recovery. The authors propose measuring aging dynamically, by tracking how people respond to and recover from standardized stressors such as exercise, vaccination or a glucose challenge, instead of relying only on resting biomarkers like epigenetic clocks. They rank longevity interventions by evidence, placing exercise and cardiometabolic control at the top and NAD+ precursors, senolytics and partial reprogramming well below.

A thermostat is judged not by the temperature in a quiet room but by how well it handles an open window. A new review argues that human aging should be judged the same way.

David Bar-Or and colleagues, writing in the journal Geriatrics, propose that aging is fundamentally a decline in “biological self-correction.” Young bodies take constant damage too, they note, but they detect it quickly, respond in proportion, repair it and then switch the response off. With age, each step can falter. Responses come late or overshoot. Repairs are incomplete. Inflammation that should end keeps smoldering. And sometimes the body settles efficiently into a worse equilibrium, such as chronically raised inflammation or blood pressure, and then defends that state as if it were normal.

This view does not discard the familiar hallmarks of aging, such as DNA damage, failing protein quality control, dysfunctional mitochondria and senescent cells. Instead it treats them as possible reasons the correction cycle breaks down. Senescence, for example, starts as a sensible defense against cancer but becomes harmful when the immune system stops clearing the arrested cells.

The practical proposal is a shift in measurement. Rather than reading biological age from a single blood draw, researchers would apply a defined stress, such as an exercise test, a vaccine or a sugary drink, and track the response over time: how far function drops, how quickly it returns, what it costs and whether reserve remains for the next challenge. The authors list ten or more trajectory features to capture.

The review is also notably sober about popular longevity strategies. NAD+ precursors reliably raise NAD+ levels in blood but have not consistently improved function in human trials. Senolytics remain preliminary in people. Partial reprogramming is still a laboratory tool with cancer risks. Even mTOR inhibition is framed carefully: the authors suggest healthy aging may depend on switching flexibly between growth and maintenance modes rather than keeping growth signaling permanently low (a position that is well known in the Longevity / rapamycin user community already).

At the top of their evidence ranking sit unglamorous interventions: physical activity, resistance training, not smoking, blood pressure and metabolic control, vaccination, sleep and diet. Exercise gets special emphasis because it is both a controlled stress and a way of training the body’s response to stress.

The weaknesses are real. The paper presents no new data, and its literature search was not systematic. The authors acknowledge that “self-correction” overlaps heavily with existing ideas such as resilience, allostasis and physiological reserve. More importantly, the review omits a body of work that has already measured recovery dynamics in humans, including analyses of blood markers showing that recovery from fluctuations slows with age. With so many possible stressors, readouts and trajectory measures, and an escape clause for “defended” unhealthy setpoints, the framework may be harder to falsify than the authors suggest.

Still, the core idea has value. A clock that reads lower after a supplement means little if you recover no better from illness, surgery or a hard week. Measuring how people bounce back, not just how they look at rest, is a reasonable next step for the field.

Actionable insights

The review generates no new data, so its practical messages rest on the human studies it cites.

  1. Resistance training. In a meta-analysis of cohort studies, any resistance training versus none was linked to 15 percent lower all-cause mortality (Cohen’s d approx. 0.09, small), with the largest reduction, about 26 percent, at roughly 60 minutes per week and no extra benefit beyond. Combining resistance and aerobic activity was linked to 40 percent lower mortality versus doing neither (d approx. 0.28). For a group with 10 percent ten-year mortality, that is about 4 fewer deaths per 100 people. These are observational associations.
  2. Lifestyle base. Adults with five low-risk habits (never smoking, regular activity, healthy weight, good diet, moderate alcohol) had projected life expectancy at age 50 that was 14.0 years longer for women and 12.2 years for men than those with none.
  3. Experimental agents. NAD+ precursors show target engagement without consistent functional benefit; senolytics remain preliminary in humans. Avoid indiscriminate stacking.
  4. Self-tracking. Recovery metrics such as heart rate variability rebound after training or glucose return-to-baseline after meals fit this framework, but none are validated as aging measures.

Context and source

Related Reading:

RapAdmin

RiboflavinButyrate-2
RiboflavinButyrate-22752×1536 490 KB

The RIBOGUT trial randomized 105 healthy Dutch adults to placebo, 50 mg/day, or 100 mg/day of oral riboflavin for two weeks, testing whether high-dose vitamin B2 could expand populations of Faecalibacterium prausnitzii, a butyrate-producing gut anaerobe repeatedly linked to gut health. The primary endpoint failed outright. F. prausnitzii abundance did not change by either fluorescence microscopy or 16S sequencing, and neither did overall microbial diversity or community composition. Secondary findings were more interesting. Fecal butyrate concentration rose in the 100 mg group, and rose more convincingly when both riboflavin arms were pooled in a post hoc analysis. Network analysis suggested the bacterial community became more interconnected. A small substudy showed non-significant upward trends in post-glucose insulin and GLP-1 at the higher dose.

The Groningen team had a specific and reasonable hypothesis. Faecalibacterium prausnitzii is one of the most abundant bacteria in the human colon and one of the most consistently depleted in inflammatory bowel disease and obesity. It makes butyrate, the short-chain fatty acid that colon cells burn for fuel and that calms local inflammation. Earlier work had shown that F. prausnitzii uses riboflavin as an electron shuttle, letting it survive in the oxygen gradient near the gut wall where it otherwise would not. Give people enough riboflavin that some escapes absorption in the small intestine and reaches the colon, the logic went, and the bacterium should flourish.

It did not. Across 105 healthy volunteers taking 50 or 100 mg daily for a fortnight, F. prausnitzii numbers held completely flat. Two independent measurement methods agreed. Overall community diversity did not budge either. Where you landed in the microbial map at the start of the trial is where you were at the end.

The riboflavin definitely arrived. Fecal and plasma riboflavin levels climbed steeply in both supplemented groups and not at all in placebo, with some of the most decisive p-values in the paper. So this was not a delivery failure. The vitamin got there and the population census refused to move.

What moved was output. Fecal butyrate rose in the 100 mg group. When the investigators combined both riboflavin arms into a single larger group, a decision made after seeing the data, the butyrate increase became clearer. Acetate rose in the 50 mg group. The bacterial interaction network, a statistical map of which organisms rise and fall together, gained connections and tightened up in the supplemented participants while the placebo network thinned out over the same period.

The interpretation the authors offer is that the same microbial community simply started working differently. More cross-feeding, more metabolic traffic, more butyrate out the far end, with the roster unchanged. Riboflavin is a precursor to FAD and FMN, cofactors that sit at the heart of bacterial electron transport, so a plausible mechanism exists for why handing a community more redox currency would raise its metabolic throughput without changing who belongs to it.

Two cautions matter. The pooling of the dose groups was decided after the fact, which is the kind of analytic choice that generates positive findings from null trials. And the study was funded by DSM Nutritional Products, which employs one author and has since brought a colon-targeted riboflavin ingredient to market built on precisely this concept.

Still, the idea that an inexpensive vitamin might shift gut metabolic function without disturbing gut ecology is worth testing properly. This study is a signal, not a verdict.

Actionable Insights

First, the headline claim is weak but not empty. Pooling both dose groups, fecal butyrate increased from a median of roughly 10 to 11 mM before supplementation to roughly 15 mM after. That is a relative increase in the neighborhood of 35 to 45 percent. Translated into a standardized effect size, the paired comparison corresponds to roughly r = 0.30 to 0.34, which converts to a Cohen’s d somewhere near 0.6 to 0.7. In plain terms, a d of 0.6 means that if you lined up people before and after, the typical person after supplementation sits above about 73 percent of their own pre-supplementation distribution. That is a real but moderate shift, not a transformation.

Second, that number is almost certainly optimistic. It comes from a within-person before-and-after comparison inside a group created after the data were seen. The honest placebo-controlled between-group test of butyrate change was never reported. In the placebo arm, butyrate actually drifted downward over the same window, which means some of the apparent gain is regression to the mean and seasonal or dietary noise rather than drug effect.

Third, be aware. 50 to 100 mg/day is roughly 40 to 90 times the adult RDA. It was safe, and generally is at higher doses like this, but there are not a lot of studies. It will turn your urine bright yellow.

Fourth, if your goal is butyrate, fermentable fiber and resistant starch have substantially stronger and better-replicated human evidence than this. Combining both approaches could be a reasonable strategy.

Context and Source

  • Open Access Paper: Riboflavin Supplementation Promotes Butyrate Production in the Absence of Gross Compositional Changes in the Gut Microbiota
  • Lead institution: Department of Medical Microbiology and Infection Prevention, University of Groningen, University Medical Center Groningen, The Netherlands.
  • Journal: Antioxidants & Redox Signaling
  • Country: The Netherlands. Co-affiliations in Australia (University of Adelaide) and Switzerland (DSM Nutritional Products AG, Kaiseraugst, and University Hospital Zurich).
  • Impact Evaluation: The impact score of this journal is 6.1, evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a Medium impact journal.

Related Reading: